Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
41
ENLV Quote, Financials, Valuation and Earnings
Last price:
$1.01
Seasonality move
:
0.75%
Day range:
$1.05 - $1.11
52-week range:
$0.66 - $2.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
14.26x
Volume:
151K
Avg. volume:
425.9K
1-year change:
--
Market cap:
$249.3M
Revenue:
--
EPS (TTM):
-$0.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
-- | -$0.03 | -- | -93.12% | $13.00 |
|
BLRX
BioLineRx Ltd.
|
$492K | -$0.77 | -95.85% | -49.07% | $20.33 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$14.3M | $0.14 | -63.51% | -2.83% | $5.80 |
|
PLUR
Pluri, Inc.
|
$638K | -$0.65 | 316.67% | -79.86% | $12.00 |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
$1.05 | $13.00 | $249.3M | -- | $0.00 | 0% | -- |
|
BLRX
BioLineRx Ltd.
|
$2.82 | $20.33 | $12.3M | -- | $0.00 | 0% | 0.78x |
|
CANF
Can-Fite BioPharma Ltd.
|
$4.44 | $2.50 | $5.8M | -- | $0.00 | 0% | 24.77x |
|
CGEN
Compugen Ltd.
|
$1.79 | $5.80 | $167.4M | 55.83x | $0.00 | 0% | 23.92x |
|
PLUR
Pluri, Inc.
|
$3.68 | $12.00 | $37M | -- | $0.00 | 0% | 22.48x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
$0.89 | -- | $7.8M | -- | $0.00 | 0% | 15.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
3.86% | 1.739 | 2.77% | 6.04x |
|
BLRX
BioLineRx Ltd.
|
36.81% | 2.493 | 69.17% | 1.84x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.875 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.410 | 2.14% | 4.24x |
|
PLUR
Pluri, Inc.
|
172.93% | 0.066 | 98.32% | 0.40x |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
2.86% | 0.265 | 1.28% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ENLV
Enlivex Therapeutics Ltd.
|
-$81K | -$2.6M | -57.56% | -59.16% | -- | -$2.3M |
|
BLRX
BioLineRx Ltd.
|
$225K | -$2.2M | -9.37% | -18.74% | -516.85% | -$2.1M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
PLUR
Pluri, Inc.
|
-$43K | -$6.5M | -93.31% | -5662.45% | -3285.86% | -$5.7M |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
-- | -$764K | -33.97% | -34.34% | -283.95% | -- |
Enlivex Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns ENLV or BLRX?
BioLineRx Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -228.81%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat BioLineRx Ltd.'s return on equity of -18.74%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M BLRXBioLineRx Ltd.52.45% -$0.22 $30.9M -
What do Analysts Say About ENLV or BLRX?
Enlivex Therapeutics Ltd. has a consensus price target of $13.00, signalling upside risk potential of 1138.1%. On the other hand BioLineRx Ltd. has an analysts' consensus of $20.33 which suggests that it could grow by 621.04%. Given that Enlivex Therapeutics Ltd. has higher upside potential than BioLineRx Ltd., analysts believe Enlivex Therapeutics Ltd. is more attractive than BioLineRx Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 BLRXBioLineRx Ltd.2 0 0 -
Is ENLV or BLRX More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.626, which suggesting that the stock is 62.626% more volatile than S&P 500. In comparison BioLineRx Ltd. has a beta of 1.321, suggesting its more volatile than the S&P 500 by 32.082%.
-
Which is a Better Dividend Stock ENLV or BLRX?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLineRx Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. BioLineRx Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or BLRX?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than BioLineRx Ltd. quarterly revenues of $429K. Enlivex Therapeutics Ltd.'s net income of -$2.2M is lower than BioLineRx Ltd.'s net income of -$981.6K. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while BioLineRx Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 0.78x for BioLineRx Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M BLRXBioLineRx Ltd.0.78x -- $429K -$981.6K
-
Which has Higher Returns ENLV or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of --. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About ENLV or CANF?
Enlivex Therapeutics Ltd. has a consensus price target of $13.00, signalling upside risk potential of 1138.1%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1026.13%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe Enlivex Therapeutics Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is ENLV or CANF More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.626, which suggesting that the stock is 62.626% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 1.068, suggesting its more volatile than the S&P 500 by 6.818%.
-
Which is a Better Dividend Stock ENLV or CANF?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or CANF?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 24.77x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M CANFCan-Fite BioPharma Ltd.24.77x -- -- --
-
Which has Higher Returns ENLV or CGEN?
Compugen Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -369.06%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About ENLV or CGEN?
Enlivex Therapeutics Ltd. has a consensus price target of $13.00, signalling upside risk potential of 1138.1%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 224.02%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Compugen Ltd., analysts believe Enlivex Therapeutics Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 CGENCompugen Ltd.5 0 0 -
Is ENLV or CGEN More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.626, which suggesting that the stock is 62.626% more volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.864, suggesting its more volatile than the S&P 500 by 186.386%.
-
Which is a Better Dividend Stock ENLV or CGEN?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or CGEN?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Compugen Ltd.'s net income of -$7M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 23.92x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M CGENCompugen Ltd.23.92x 55.83x $1.9M -$7M
-
Which has Higher Returns ENLV or PLUR?
Pluri, Inc. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -3470.71%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat Pluri, Inc.'s return on equity of -5662.45%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M PLURPluri, Inc.-21.72% -$0.71 $25.4M -
What do Analysts Say About ENLV or PLUR?
Enlivex Therapeutics Ltd. has a consensus price target of $13.00, signalling upside risk potential of 1138.1%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 226.09%. Given that Enlivex Therapeutics Ltd. has higher upside potential than Pluri, Inc., analysts believe Enlivex Therapeutics Ltd. is more attractive than Pluri, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 PLURPluri, Inc.1 0 0 -
Is ENLV or PLUR More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.626, which suggesting that the stock is 62.626% more volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.181%.
-
Which is a Better Dividend Stock ENLV or PLUR?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or PLUR?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $198K. Enlivex Therapeutics Ltd.'s net income of -$2.2M is higher than Pluri, Inc.'s net income of -$6.9M. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 22.48x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M PLURPluri, Inc.22.48x -- $198K -$6.9M
-
Which has Higher Returns ENLV or XTLB?
XTL Biopharmaceuticals Ltd. has a net margin of -- compared to Enlivex Therapeutics Ltd.'s net margin of -341.36%. Enlivex Therapeutics Ltd.'s return on equity of -59.16% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.
Company Gross Margin Earnings Per Share Invested Capital ENLVEnlivex Therapeutics Ltd.-- -$0.09 $18.2M XTLBXTL Biopharmaceuticals Ltd.-- -$0.16 $5.9M -
What do Analysts Say About ENLV or XTLB?
Enlivex Therapeutics Ltd. has a consensus price target of $13.00, signalling upside risk potential of 1138.1%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3273.44%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Enlivex Therapeutics Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Enlivex Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ENLVEnlivex Therapeutics Ltd.1 1 0 XTLBXTL Biopharmaceuticals Ltd.0 0 0 -
Is ENLV or XTLB More Risky?
Enlivex Therapeutics Ltd. has a beta of 1.626, which suggesting that the stock is 62.626% more volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.178, suggesting its more volatile than the S&P 500 by 17.838%.
-
Which is a Better Dividend Stock ENLV or XTLB?
Enlivex Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enlivex Therapeutics Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ENLV or XTLB?
Enlivex Therapeutics Ltd. quarterly revenues are --, which are smaller than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Enlivex Therapeutics Ltd.'s net income of -$2.2M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Enlivex Therapeutics Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enlivex Therapeutics Ltd. is -- versus 15.82x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ENLVEnlivex Therapeutics Ltd.-- -- -- -$2.2M XTLBXTL Biopharmaceuticals Ltd.15.82x -- $162K -$553K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
